No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard medical research council induction chemotherapy.
作者信息
Jensen Morten Krogh
出版信息
J Clin Oncol. 2013 May 1;31(13):1700. doi: 10.1200/JCO.2012.47.9238. Epub 2013 Mar 25.
PMID:23530103
Abstract
摘要
Zotero 插件